Lockerman Financial Group Inc. Purchases 53 Shares of Amgen Inc. (NASDAQ:AMGN)

Lockerman Financial Group Inc. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,261 shares of the medical research company’s stock after purchasing an additional 53 shares during the quarter. Lockerman Financial Group Inc.’s holdings in Amgen were worth $406,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Fisher Asset Management LLC raised its stake in shares of Amgen by 4.0% during the 4th quarter. Fisher Asset Management LLC now owns 78,753 shares of the medical research company’s stock valued at $22,682,000 after purchasing an additional 3,049 shares during the period. ICA Group Wealth Management LLC purchased a new stake in shares of Amgen in the fourth quarter worth about $188,000. Leo Wealth LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $449,000. Nomura Holdings Inc. purchased a new position in Amgen during the fourth quarter valued at approximately $3,104,000. Finally, Duncan Williams Asset Management LLC bought a new stake in Amgen during the 1st quarter worth approximately $590,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AMGN. TD Cowen raised their price target on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald started coverage on Amgen in a research note on Friday, September 27th. They set an “overweight” rating and a $405.00 price objective for the company. Argus upped their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Morgan Stanley lowered their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $326.95.

Amgen Trading Up 0.1 %

Shares of Amgen stock traded up $0.47 during trading on Tuesday, reaching $325.09. 1,820,819 shares of the stock were exchanged, compared to its average volume of 2,459,254. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85. The firm has a market cap of $174.39 billion, a price-to-earnings ratio of 46.37, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The stock’s fifty day moving average is $326.05 and its 200 day moving average is $311.20.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter in the prior year, the business posted $5.00 earnings per share. Amgen’s quarterly revenue was up 20.1% compared to the same quarter last year. As a group, equities research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.77%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.